UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18

UBS analyst Alice Nettleton has initiated coverage on AbCellera Biologics (NASDAQ: ABCL) with a Buy rating. The firm has set a price target of $18 for the company's stock.